News August 2024

Smivet BV is proud to announce the recent validation of its IP applications for an in vitro produced Tetanus Antitoxin for human and veterinary use, #onehealth. Patents were granted and issued after assessment by the experts of the People's Republic of China (January 2024) and the United States of America (August 2024). Smivet BV continues its efforts to strengthen and further build its international intellectual property portfolio.